ATAI Life Sciences NV has announced an update on the Phase 2b trial of inidascamine, a treatment for cognitive impairment associated with schizophrenia $(CIAS)$. Initial results indicate a numerical improvement in cognitive and functional measures across both active treatment arms compared to a placebo. However, the study did not achieve statistical significance on the primary endpoint. The safety and tolerability profile of inidascamine remains favorable. Recognify Life Sciences, a subsidiary of ATAI, plans to present additional results at upcoming scientific meetings. The company will continue to evaluate strategic options for inidascamine based on the comprehensive data set, which will include secondary endpoints and subgroup analyses.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.